Multidisciplinary diagnostics of chronic lymphocytic leukemia: European Research Initiative on CLL - ERIC recommendations

Recent advances in chronic lymphocytic leukemia (CLL) includes description of disease genomic landscape, inclusion of prognostic relevant genetic tests in CLL workflow and evaluation of minimal residual disease (MRD) in parallel with the increase availability of novel therapy agents. In this review,...

Full description

Saved in:
Bibliographic Details
Published in:Hematology, Transfusion and Cell Therapy Transfusion and Cell Therapy, 2020-07, Vol.42 (3), p.269-274
Main Authors: Zalcberg, Ilana, D'Andrea, Mariana Gamma, Monteiro, Lucia, Pimenta, Glicínia, Xisto, Beth
Format: Article
Language:English
Subjects:
Chronic lymphocytic leukemia
DEL(17P) and TP53 mutations
Flow cytometry
MEDICINE, GENERAL & INTERNAL
Minimal residual disease
Mutational status of IGHV
Review
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recent advances in chronic lymphocytic leukemia (CLL) includes description of disease genomic landscape, inclusion of prognostic relevant genetic tests in CLL workflow and evaluation of minimal residual disease (MRD) in parallel with the increase availability of novel therapy agents. In this review, the theoretical and practical aspects of response assessment have been discussed. These are based on updated recommendations of the European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) for genetic tests (TP53 mutation and IGHV status) and flow cytometry analysis for CLL. Methodological approaches and interpretation of results were also discussed. .
ISSN:2531-1379
2531-1387
2531-1387
DOI:10.1016/j.htct.2019.07.006